Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Author Correction: Felodipine induces autophagy in mouse brains with pharmacokinetics amenable to repurposing.

Siddiqi FH, Menzies FM, Lopez A, Stamatakou E, Karabiyik C, Ureshino R, Ricketts T, Jimenez-Sanchez M, Esteban MA, Lai L, Tortorella MD, Luo Z, Liu H, Metzakopian E, Fernandes HJR, Bassett A, Karran E, Miller BL, Fleming A, Rubinsztein DC.

Nat Commun. 2019 Jun 4;10(1):2530. doi: 10.1038/s41467-019-10536-y.

2.

Felodipine induces autophagy in mouse brains with pharmacokinetics amenable to repurposing.

Siddiqi FH, Menzies FM, Lopez A, Stamatakou E, Karabiyik C, Ureshino R, Ricketts T, Jimenez-Sanchez M, Esteban MA, Lai L, Tortorella MD, Luo Z, Liu H, Metzakopian E, Fernandes HJR, Bassett A, Karran E, Miller BL, Fleming A, Rubinsztein DC.

Nat Commun. 2019 Apr 18;10(1):1817. doi: 10.1038/s41467-019-09494-2. Erratum in: Nat Commun. 2019 Jun 4;10(1):2530.

3.

Genome-Scale CRISPRa Screen Identifies Novel Factors for Cellular Reprogramming.

Yang J, Rajan SS, Friedrich MJ, Lan G, Zou X, Ponstingl H, Garyfallos DA, Liu P, Bradley A, Metzakopian E.

Stem Cell Reports. 2019 Apr 9;12(4):757-771. doi: 10.1016/j.stemcr.2019.02.010. Epub 2019 Mar 21.

4.

ATM orchestrates the DNA-damage response to counter toxic non-homologous end-joining at broken replication forks.

Balmus G, Pilger D, Coates J, Demir M, Sczaniecka-Clift M, Barros AC, Woods M, Fu B, Yang F, Chen E, Ostermaier M, Stankovic T, Ponstingl H, Herzog M, Yusa K, Martinez FM, Durant ST, Galanty Y, Beli P, Adams DJ, Bradley A, Metzakopian E, Forment JV, Jackson SP.

Nat Commun. 2019 Jan 8;10(1):87. doi: 10.1038/s41467-018-07729-2.

5.

SRPK1 maintains acute myeloid leukemia through effects on isoform usage of epigenetic regulators including BRD4.

Tzelepis K, De Braekeleer E, Aspris D, Barbieri I, Vijayabaskar MS, Liu WH, Gozdecka M, Metzakopian E, Toop HD, Dudek M, Robson SC, Hermida-Prado F, Yang YH, Babaei-Jadidi R, Garyfallos DA, Ponstingl H, Dias JML, Gallipoli P, Seiler M, Buonamici S, Vick B, Bannister AJ, Rad R, Prinjha RK, Marioni JC, Huntly B, Batson J, Morris JC, Pina C, Bradley A, Jeremias I, Bates DO, Yusa K, Kouzarides T, Vassiliou GS.

Nat Commun. 2018 Dec 19;9(1):5378. doi: 10.1038/s41467-018-07620-0.

6.

Predicting the mutations generated by repair of Cas9-induced double-strand breaks.

Allen F, Crepaldi L, Alsinet C, Strong AJ, Kleshchevnikov V, De Angeli P, Páleníková P, Khodak A, Kiselev V, Kosicki M, Bassett AR, Harding H, Galanty Y, Muñoz-Martínez F, Metzakopian E, Jackson SP, Parts L.

Nat Biotechnol. 2018 Nov 27. doi: 10.1038/nbt.4317. [Epub ahead of print]

PMID:
30480667
7.

WINDOW consortium: A path towards increased therapy efficacy against glioblastoma.

Abdul KU, Houweling M, Svensson F, Narayan RS, Cornelissen FMG, Küçükosmanoglu A, Metzakopian E, Watts C, Bailey D, Wurdinger T, Westerman BA.

Drug Resist Updat. 2018 Sep;40:17-24. doi: 10.1016/j.drup.2018.10.001. Epub 2018 Oct 30. Review.

PMID:
30439622
8.

UTX-mediated enhancer and chromatin remodeling suppresses myeloid leukemogenesis through noncatalytic inverse regulation of ETS and GATA programs.

Gozdecka M, Meduri E, Mazan M, Tzelepis K, Dudek M, Knights AJ, Pardo M, Yu L, Choudhary JS, Metzakopian E, Iyer V, Yun H, Park N, Varela I, Bautista R, Collord G, Dovey O, Garyfallos DA, De Braekeleer E, Kondo S, Cooper J, Göttgens B, Bullinger L, Northcott PA, Adams D, Vassiliou GS, Huntly BJP.

Nat Genet. 2018 Jun;50(6):883-894. doi: 10.1038/s41588-018-0114-z. Epub 2018 May 7.

9.

Dynamics of Indel Profiles Induced by Various CRISPR/Cas9 Delivery Methods.

Kosicki M, Rajan SS, Lorenzetti FC, Wandall HH, Narimatsu Y, Metzakopian E, Bennett EP.

Prog Mol Biol Transl Sci. 2017;152:49-67. doi: 10.1016/bs.pmbts.2017.09.003. Epub 2017 Nov 6.

PMID:
29150004
10.

Transcriptional repression of Plxnc1 by Lmx1a and Lmx1b directs topographic dopaminergic circuit formation.

Chabrat A, Brisson G, Doucet-Beaupré H, Salesse C, Schaan Profes M, Dovonou A, Akitegetse C, Charest J, Lemstra S, Côté D, Pasterkamp RJ, Abrudan MI, Metzakopian E, Ang SL, Lévesque M.

Nat Commun. 2017 Oct 16;8(1):933. doi: 10.1038/s41467-017-01042-0.

11.

Enhancing the genome editing toolbox: genome wide CRISPR arrayed libraries.

Metzakopian E, Strong A, Iyer V, Hodgkins A, Tzelepis K, Antunes L, Friedrich MJ, Kang Q, Davidson T, Lamberth J, Hoffmann C, Davis GD, Vassiliou GS, Skarnes WC, Bradley A.

Sci Rep. 2017 May 22;7(1):2244. doi: 10.1038/s41598-017-01766-5.

12.

A single-copy Sleeping Beauty transposon mutagenesis screen identifies new PTEN-cooperating tumor suppressor genes.

de la Rosa J, Weber J, Friedrich MJ, Li Y, Rad L, Ponstingl H, Liang Q, de Quirós SB, Noorani I, Metzakopian E, Strong A, Li MA, Astudillo A, Fernández-García MT, Fernández-García MS, Hoffman GJ, Fuente R, Vassiliou GS, Rad R, López-Otín C, Bradley A, Cadiñanos J.

Nat Genet. 2017 May;49(5):730-741. doi: 10.1038/ng.3817. Epub 2017 Mar 20.

13.

A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia.

Tzelepis K, Koike-Yusa H, De Braekeleer E, Li Y, Metzakopian E, Dovey OM, Mupo A, Grinkevich V, Li M, Mazan M, Gozdecka M, Ohnishi S, Cooper J, Patel M, McKerrell T, Chen B, Domingues AF, Gallipoli P, Teichmann S, Ponstingl H, McDermott U, Saez-Rodriguez J, Huntly BJP, Iorio F, Pina C, Vassiliou GS, Yusa K.

Cell Rep. 2016 Oct 18;17(4):1193-1205. doi: 10.1016/j.celrep.2016.09.079.

14.

Genome-wide characterisation of Foxa1 binding sites reveals several mechanisms for regulating neuronal differentiation in midbrain dopamine cells.

Metzakopian E, Bouhali K, Alvarez-Saavedra M, Whitsett JA, Picketts DJ, Ang SL.

Development. 2015 Apr 1;142(7):1315-24. doi: 10.1242/dev.115808.

15.

A conditional piggyBac transposition system for genetic screening in mice identifies oncogenic networks in pancreatic cancer.

Rad R, Rad L, Wang W, Strong A, Ponstingl H, Bronner IF, Mayho M, Steiger K, Weber J, Hieber M, Veltkamp C, Eser S, Geumann U, Öllinger R, Zukowska M, Barenboim M, Maresch R, Cadiñanos J, Friedrich M, Varela I, Constantino-Casas F, Sarver A, Ten Hoeve J, Prosser H, Seidler B, Bauer J, Heikenwälder M, Metzakopian E, Krug A, Ehmer U, Schneider G, Knösel T, Rümmele P, Aust D, Grützmann R, Pilarsky C, Ning Z, Wessels L, Schmid RM, Quail MA, Vassiliou G, Esposito I, Liu P, Saur D, Bradley A.

Nat Genet. 2015 Jan;47(1):47-56. doi: 10.1038/ng.3164. Epub 2014 Dec 8.

PMID:
25485836
16.

Foxa1 and foxa2 are required for the maintenance of dopaminergic properties in ventral midbrain neurons at late embryonic stages.

Stott SR, Metzakopian E, Lin W, Kaestner KH, Hen R, Ang SL.

J Neurosci. 2013 May 1;33(18):8022-34. doi: 10.1523/JNEUROSCI.4774-12.2013.

17.

Genome-wide characterization of Foxa2 targets reveals upregulation of floor plate genes and repression of ventrolateral genes in midbrain dopaminergic progenitors.

Metzakopian E, Lin W, Salmon-Divon M, Dvinge H, Andersson E, Ericson J, Perlmann T, Whitsett JA, Bertone P, Ang SL.

Development. 2012 Jul;139(14):2625-34. doi: 10.1242/dev.081034. Epub 2012 Jun 13.

18.

Foxa1 and Foxa2 positively and negatively regulate Shh signalling to specify ventral midbrain progenitor identity.

Mavromatakis YE, Lin W, Metzakopian E, Ferri AL, Yan CH, Sasaki H, Whisett J, Ang SL.

Mech Dev. 2011 Jan-Feb;128(1-2):90-103. doi: 10.1016/j.mod.2010.11.002. Epub 2010 Nov 17.

19.

Foxa1 and Foxa2 function both upstream of and cooperatively with Lmx1a and Lmx1b in a feedforward loop promoting mesodiencephalic dopaminergic neuron development.

Lin W, Metzakopian E, Mavromatakis YE, Gao N, Balaskas N, Sasaki H, Briscoe J, Whitsett JA, Goulding M, Kaestner KH, Ang SL.

Dev Biol. 2009 Sep 15;333(2):386-96. doi: 10.1016/j.ydbio.2009.07.006. Epub 2009 Jul 14.

Supplemental Content

Loading ...
Support Center